12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Glembatumumab vedotin: Completed Phase IIb enrollment

Celldex completed enrollment in the open-label, U.S. Phase IIb EMERGE trial evaluating 1.88 mg/kg IV glembatumumab vedotin given on day 1 of each 21-day cycle vs. single...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >